SequelSEC

IDEAYA Biosciences, Inc. IDYA

Pharmaceutical Preparations · CIK 0001676725 · Fiscal year ends 1231

AnnualQuarterlyTTM
Revenue
$234.13M
Fiscal year ended 2026-06-30
Operating income
-$216.95M
Fiscal year ended 2026-06-30
Free cash flow
Unavailable
Fiscal year ended 2026-06-30

IDEAYA Biosciences, Inc. (IDYA) reported revenue of $234.13M and net income of -$175.02M for the fiscal year ended 2026-06-30. This page shows 1 annual period of income statement, balance sheet and cash flow figures normalized from IDEAYA Biosciences, Inc.’s SEC filings, each linked to the filing it came from. It is classified by the SEC under Pharmaceutical Preparations.

Income

IDEAYA Biosciences, Inc. income by fiscal year, in US dollars, normalized from SEC filings.
Metric2026-06-30
Revenue$234.13M
Cost of revenueUnavailable
Gross profitUnavailable
Operating income-$216.95M
Net income-$175.02M
Research & development$374.01M
Weighted-average diluted sharesUnavailable
Pretax incomeUnavailable
Income tax expenseUnavailable
Diluted EPS$-1.94
Selling, general & administrativeUnavailable
General & administrative$77.07M
Selling & marketingUnavailable

Balance

IDEAYA Biosciences, Inc. balance by fiscal year, in US dollars, normalized from SEC filings.
Metric2026-06-30
Cash & equivalents$272.59M
Total assets$1.31B
Current assets$864.02M
Total liabilities$110.79M
Current liabilities$82.68M
Total equity incl. NCI$1.20B
Temporary (mezzanine) equityUnavailable
InventoryUnavailable
Accounts receivableUnavailable
GoodwillUnavailable
Long-term debtUnavailable
Accounts payable$30.51M

Cash flow

IDEAYA Biosciences, Inc. cash flow by fiscal year, in US dollars, normalized from SEC filings.
Metric2026-06-30
Operating cash flowUnavailable
Capital expendituresUnavailable
Investing cash flowUnavailable
Financing cash flowUnavailable
Net change in cashUnavailable
Stock-based compensationUnavailable
Common dividends paidUnavailable
Common share repurchasesUnavailable
Depreciation & amortization$2.79M

Derived

IDEAYA Biosciences, Inc. derived by fiscal year, in US dollars, normalized from SEC filings.
Metric2026-06-30
Free cash flowUnavailable
Gross marginUnavailable
Operating margin-92.7%
FCF marginUnavailable
SBC / revenueUnavailable
Current ratio10.45x
Revenue YoY growthUnavailable
Net margin-74.8%
R&D / revenue159.7%
CapEx / revenueUnavailable
Long-term debt / equityUnavailable
Effective tax rateUnavailable

Amounts are abbreviated; the exact reported value is carried in each cell. — means unavailable, not zero. Open IDYA in the interactive workspace to inspect any figure back to its filing.

Source filings

10-Q · Filed 2026-08-04View SEC filing
10-Q · Filed 2026-05-05View SEC filing
10-K · Filed 2026-02-17View SEC filing
10-Q · Filed 2025-11-04View SEC filing
10-Q · Filed 2025-08-05View SEC filing
10-Q · Filed 2025-05-06View SEC filing

Companies in the same industry

AAGH AARD ABBV ABCL ABEO ABT ABUS ABVC ACAD ACET ACRS ACRV

Every accounting identity this site checks — the balance sheet, the gross profit bridge and the cash flow statement — reconciles in every period shown.